| Atypical Hemolytic Uremic Syndrome
Ultomiris vs Soliris
Side-by-side clinical, coverage, and cost comparison for atypical hemolytic uremic syndrome.Deep comparison between: Ultomiris vs Soliris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliris has a higher rate of injection site reactions vs Ultomiris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliris but not Ultomiris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ultomiris
Soliris
At A Glance
IV infusion
Every 4-8 weeks
C5 complement inhibitor
IV infusion
Every 2 weeks
Complement C5 inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome (5 to <40 kg) Weight-based IV loading dose (600-1,200 mg), followed by weight-based maintenance dose every 4 weeks (5 to <20 kg) or every 8 weeks (20 to <40 kg), starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (>=40 kg) Weight-based IV loading dose (2,400-3,000 mg), followed by weight-based maintenance dose (3,000-3,600 mg) every 8 weeks, starting 2 weeks after loading dose.
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=10%) Upper respiratory tract infection, headache, diarrhea, nausea, vomiting, hypertension, pyrexia, back pain, arthralgia, COVID-19
Serious Meningococcal infections, other infections (including fatal COVID-19 pneumonia and sepsis), infusion-related reactions
Postmarketing Anaphylaxis, cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Pharmacology
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds complement protein C5 with high affinity, preventing its cleavage to C5a (proinflammatory anaphylatoxin) and C5b (initiating subunit of the membrane attack complex), thereby inhibiting MAC formation and terminal complement-mediated tissue damage in PNH, aHUS, gMG, and NMOSD.
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ultomiris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Soliris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Ultomiris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Soliris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ultomiris
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Soliris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Ultomiris.
No savings programs available for Soliris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UltomirisView full Ultomiris profile
SolirisView full Soliris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.